<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>259693</rcn>
  <id>101138971</id>
  <acronym>DCanVAX</acronym>
  <teaser>Following decades of development, therapeutic cancer vaccines are beginning to gain momentum in demonstrating therapeutic effects, and they represent a particularly promising approach. The aim of therapeutic cancer vaccines is to stimulate immunity against tumor antigens...</teaser>
  <objective>Following decades of development, therapeutic cancer vaccines are beginning to gain momentum in demonstrating therapeutic effects, and they represent a particularly promising approach. The aim of therapeutic cancer vaccines is to stimulate immunity against tumor antigens, usually through the use of whole cells, peptides, or nucleic acids (i.e. mRNAs). Dendritic cell- (DC) based vaccines represent particularly interesting candidates for therapeutic cancer vaccine products due to their ability to cross-present antigens to T cells, thereby driving adaptive immune responses through induction of antigen-specific cytotoxic T lymphocytes. Despite the potential of DC-based cancer vaccines, several major limitations have hindered their success in clinical studies. These limitations include insufficient ex vivo maturation of DCs and challenges in selecting optimal tumor antigens to target.   The aim of DCanVAX is to develop a novel oncolytic virus-based dendritic cell vaccine approach for systemic therapy of solid cancers. We propose that the use of a highly immuno-oncolytic virus as a mechanism to lyse tumor cells ex-vivo, will lead to the release of the entire tumor antigen library, as well as a cocktail of danger signals in response to the virus infection. By applying this highly immunogenic lysate to autologous DCs, an optimized and personalized DC vaccine can be generated. This method overcomes the major challenges that have been encountered by DC vaccine approaches in the clinic, by providing a potent mechanism of DC maturation and activation, while simultaneously exposing the DCs to the complete repertoire of tumor antigens that are specific to the patient, leading to potent and broad tumor-specific immune responses against the cancer. This approach can be developed for multiple solid cancer indications and combined with other immunotherapy approaches for potentially synergistic therapeutic effects.</objective>
  <title>A novel immuno-oncolytic virus-based dendritic cell therapeutic cancer vaccine</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>150000</ecMaxContribution>
  <startDate>2024-02-01</startDate>
  <endDate>2025-07-31</endDate>
  <ecSignatureDate>2024-01-19</ecSignatureDate>
  <duration>18</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101138971</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-10-20 17:38:03</sourceUpdateDate>
  <contentCreationDate>2024-01-26 12:58:49</contentCreationDate>
  <contentUpdateDate>2025-10-20 17:38:03</contentUpdateDate>
  <lastUpdateDate>2025-11-24 11:45:49</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>455815</rcn>
        <id>455815-oncolytic-virus-releases-immunogenic-lysate-leading-to-personalised-vaccines</id>
        <title>Oncolytic virus releases immunogenic lysate leading to personalised vaccines</title>
        <contentUpdateDate>2025-04-09 15:04:00</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode>/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55832</rcn>
        <title>ERC-2023-POC</title>
        <identifier>ERC-2023-POC</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55832</rcn>
        <title>ERC-2023-POC</title>
        <identifier>ERC-2023-POC</identifier>
      </call>
      <organization netEcContribution="150000" totalCost="0" source="corda" order="1" ecContribution="150000" terminated="false" sme="false" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1918034</rcn>
        <id>999875710</id>
        <vatNumber>DE129523996</vatNumber>
        <legalName>KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)</legalName>
        <shortName>TUM-MED</shortName>
        <address>
          <street>ISMANINGER STRASSE 22</street>
          <city>Muenchen</city>
          <postalCode>81675</postalCode>
          <country>DE</country>
          <postBox>N/A</postBox>
          <url>http://www.mri.tum.de</url>
          <geolocation>48.1370128,11.598724</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode>/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>München, Kreisfreie Stadt</name>
              <rcn>221782082</rcn>
              <nutsCode>DE212</nutsCode>
              <parents>
                <region>
                  <name>Oberbayern</name>
                  <rcn>221782120</rcn>
                  <nutsCode>DE21</nutsCode>
                  <parents>
                    <region>
                      <name>Bayern</name>
                      <rcn>221784616</rcn>
                      <nutsCode>DE2</nutsCode>
                      <parents>
                        <region>
                          <name>Germany</name>
                          <rcn>221940264</rcn>
                          <nutsCode>DE</nutsCode>
                          <euCode>DE</euCode>
                          <isoCode>DE</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Germany</name>
              <rcn>221940264</rcn>
              <nutsCode>DE</nutsCode>
              <euCode>DE</euCode>
              <isoCode>DE</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>707186</rcn>
        <id>HORIZON_ERC-2023-POC</id>
        <code>ERC-2023-POC</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC PROOF OF CONCEPT GRANTS</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1392750</rcn>
        <id>101138971_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - DCanVAX (A novel immuno-oncolytic virus-based dendritic cell therapeutic cancer vaccine)</title>
        <description>periodic</description>
        <teaser>Dendritic cells are a heterogeneous group of innate immune cells that induce adaptive immune responses to cancer. They retrieve, process and present tumour-derived antigens to naive T cells, thereby activating them. DC-based vaccines could be particularly potent via such...</teaser>
        <sourceUpdateDate>2025-11-18 15:19:37</sourceUpdateDate>
        <contentUpdateDate>2025-11-18 15:19:37</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/341/325</code>
        <title>virology</title>
        <displayCode>/natural sciences/biological sciences/microbiology/virology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/315/997</code>
        <title>biomolecules</title>
        <displayCode>/natural sciences/biological sciences/biochemistry/biomolecules</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/159/653/1439</code>
        <title>vaccines</title>
        <displayCode>/medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drugs/vaccines</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode>/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="40">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="40">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-ERC-POC</code>
        <title>HORIZON ERC Proof of Concept Grants</title>
        <description>HORIZON ERC Proof of Concept Grants</description>
        <displayCode>/HORIZON ERC Proof of Concept Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>